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Hemostasis encompasses a set of tightly regulated processes that govern blood clotting, platelet activation, and
vascular repair. Upon vascular injury, the hemostatic system initiates a series of vascular events and activates
extravascular receptors that act in concert to seal off the damage. Blood clotting is subsequently attenuated by a
plethora of inhibitors that prevent excessive clot formation and eventual thrombosis. The endothelium which
resides at the interface between the blood and surrounding tissues, serves an integral role in the hemostatic
system. Depending on specific tissue needs and local stresses, endothelial cells are capable of evoking either
antithrombotic or prothrombotic events. Healthy endothelial cells express antiplatelet and anticoagulant agents
that prevent platelet aggregation and fibrin formation, respectively. In the face of endothelial dysfunction,
endothelial cells trigger fibrin formation, as well as platelet adhesion and aggregation. Finally, endothelial cells
release pro-fibrinolytic agents that initiate fibrinolysis to degrade the clot. Taken together, a functional endothelium
is essential to maintain hemostasis and prevent thrombosis. Thus, a greater understanding into the role of the
endothelium can provide new avenues for exploration and novel therapies for the management of thromboembolisms.
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The endothelium has been described as a cellophane
type barrier that separates the blood from the surround-
ing tissue. Although the endothelium is less than 0.2 μm
thick, it is comprised of 1 to 6 × 1013 endothelial cells
with a total surface area of 4000–7000 m2 and weighing
approximately 1 kg in an average-sized human [1].
Instead of playing merely a passive role, the endothelium
is better described as a dynamic organ that regulates its
environment and responds to external stresses. Some of
the functions of the endothelium include regulating
vascular tone, cellular adhesion, smooth muscle cell pro-
liferation, and vessel wall inflammation. In addition, the
endothelium serves as a hemocompatible lining that
helps to maintain blood flow and regulate the blood
coagulation system. Upon vascular injury, cellular and
protein materials congregate at the site of injury to cre-
ate a stable blood clot, which prevents excessive blood
loss. The significance of appropriate blood coagulation
control is apparent during the development of throm-
bosis. Thrombosis is the formation of an occlusive clot* Correspondence: vermasu@smh.ca
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tissue and organs and restricts the delivery of nutrients
and oxygen, resulting in localized tissue and organ ne-
crosis. Large occlusive clots (thrombi) can break off and
embolize to form secondary thrombi in distal locations.
The process of thrombosis followed by embolism is col-
lectively termed, thromboembolism and can culminate
in a variety of local or chronic disorders. For example,
acute arterial thrombosis is triggered upon the rupture
of an atherosclerotic plaque, and is the predominant
cause of myocardial infarctions (heart attacks) and
strokes [2]. Similarly, venous thromboembolism can be
triggered by disturbed blood flow, hypercoagulable condi-
tions, such as procoagulant changes in the blood, or endo-
thelial activation, and is the major cause of deep vein
thrombosis and pulmonary embolism [2, 3]. Since the
endothelium is located at the nexus of hemostasis and
thrombosis, a clear understanding of how endothelial-
derived molecules contribute to hemostasis and throm-
bosis is vital for the identification of potential therapeutic
targets and design of novel therapies for acute thrombosis.General functions of the endothelium
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that are distinct to each vascular bed [4, 5]. The main
function of the endothelium is to regulate systemic blood
flow and tissue perfusion through changes in vessel diam-
eter and vascular tone, performed in conjunction with
underlying smooth muscle cells and pericytes. In addition
to regulating systemic blood flow, the endothelium acts as
a barrier that selectively controls the movement of fluid,
ions and other macromolecules between the circulating
blood and surrounding tissues by coordinating the inter-
endothelial adherens and tight junction complexes [6].
While serving as a selective barrier, the endothelium
also regulates the recruitment and extravasation of
pro-inflammatory leukocytes in response to tissue
damage and infection through expression of cell adhesion
molecules and cytokines [7, 8]. Endothelial cells have a
critical role in the healing process after wounding or in-
flammation. They act as the vector of angiogenesis, the
formation of new blood vessels, which is essential for
proper formation of granulation tissue and tissue repair as
well as for re-canalization of mural and obstructing fibrin
clots. Finally, the luminal surface of the endothelium ex-
presses a plethora of molecules that regulate the activation
of platelets and the coagulation cascade, thereby maintain-
ing blood flow and preventing thrombus formation after
vessel injury [9, 10].
Vessel- and tissue-specific functions of endothelial
cells
Endothelial cells line the vessel walls of arteries, veins,
and microvessels. The local shear stress, blood oxygen-
ation, and smooth muscle cell content vary between
these vessels and consequently the endothelial cells in
the various vascular beds respond differentially to pro-
coagulant signaling. Endothelial cells are dynamic and
adapt their phenotype according to the nature of the
local milieu [11, 12]. For example, vascular shear stress
can influence the coagulant potential of endothelial cells.
Arterial shear stress can induce the transcription factors
Kruppel Like Factor (KLF) 2 and KLF 4 and attenuate
coagulation in atherosclerosis-poor regions, but has no
effect in atherosclerosis-prone areas with disturbed
blood flow [13, 14]. Likewise, reduced venous shear
stress can induce hypoxia and stimulate the release of P-
selectin and von Willebrand factor from endothelial
cells. The nature of the shear stress also has a significant
influence on the type of thrombi that forms. Arterial
clots form under high shear stress after atherosclerotic
plaque rupture and are rich in platelets, giving the
appearance of a white clot. In contrast, venous thrombi
develop under low shear stress and are rich in fibrin and
red blood cells, giving the appearance of a red clot. Venous
thrombosis is particularly prevalent in the lower limbs, due
to a variety of circumstances, including disturbed flow orlocal hypoxia. Of note, venous thrombi are exceptionally
prone to embolism due to high availability of the fibrinoly-
sis regulator, tissue-type plasminogen activator (t-PA) in
the venous system. Microvascular endothelial cells within
arteries and veins have distinctive features [15]. Surface
receptors, such as thrombomodulin, while abundantly
present in many types of endothelial cells, are poorly
expressed or absent in brain microvascular and liver sinus-
oidal endothelial cells [16]. Microvascular endothelial cells
also possess extensive phenotypic heterogeneity depending
on their location [17]. Finally, the location of the endothe-
lial cells also plays a role in the endothelial response. For
example, pulmonary endothelial cells experience rapid
changes in pressure from low-pressure, high-volume dur-
ing gas exchange to high-pressure, low volume bronchial
circulation during oxygen delivery to the bronchial tree.
Moreover, pulmonary capillary endothelial cells are
exposed to the highest level of oxygen compared with
other vascular beds in the body. Taken together, although
there are a wide variety of endothelial cells, they are similar
in that they are all capable of evoking an array of responses
that is based on cues provided by the local environment.
The blood coagulation system
In the face of vascular injury, a chain reaction of pro-
inflammatory and wound-healing responses is rapidly
triggered. As part of the wound-healing response, a
stable blood clot, consisting of aggregated platelets and a
mesh of cross-linked fibrin protein, is formed to prevent
excessive blood loss [18]. Traditionally, blood coagulation
is described as occurring in two phases, primary and sec-
ondary hemostasis, wherein platelets first aggregate to
form the initial platelet plug followed by activation of the
coagulation system to form the fibrin clot. Depictions of
blood coagulation have evolved significantly and now
showcase the complex interplay between platelets, the co-
agulation system, and vessel wall to clot formation. This
intricate network can be described as the cell-based model
of coagulation. In short, blood coagulation is categorized
into three phases: initiation, amplification, and propaga-
tion. Initiation occurs upon vascular injury with resultant
activation of the endothelium, consisting of activated
endothelial cells, and exposure to sub-endothelial cells
that include amongst others smooth muscle cells and fi-
broblasts. Sub-endothelial collagen is exposed to the blood
and mediates the initial adhesion of circulating platelets to
the exposed collagen surface via von Willebrand factor.
The platelet aggregate that forms is responsible for stop-
ping blood loss. In parallel to these events, activated endo-
thelial cells and smooth muscle cells express the potent
pro-coagulant molecule, tissue factor (TF), which binds
with circulating coagulation factor (f) VII. TF acts as a co-
factor for fVII to promote the proteolysis and activation of
fVII to become active fVII (fVIIa), wherein TF also binds
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complex then goes on to proteolytically cleave fIX and fX
into fIXa and fXa, respectively. FIXa serves to generate
more fXa and fXa serves to generate thrombin. In the
amplification phase, circulating platelets that have adhered
to the site of injury become activated by thrombin and
form a platelet aggregate. This provides a surface for the
activation of other procoagulant factors. Concomitantly,
thrombin proteolytically cleaves platelet-derived fV and
circulating fVIII into fVa and fVIIIa, respectively. In
addition, thrombin converts fXI into fXIa, which pro-
motes further fIXa generation. In the final propagation
phase, thrombin generation is amplified on the surfaces of
activated platelets. FVa binds with fXa to form the pro-
thrombinase complex, whereas fVIIIa binds with fIXa to
form the intrinsic tenase complex. The prothrombinase
and intrinsic tenase complexes serve to enhance the activ-
ities of fXa and fIXa, generating sufficient quantities of
thrombin to produce large amounts of insoluble fibrin. In
this phase, thrombin also cleaves fXIII into fXIIIa, which
covalently cross-links fibrin chains to form a large fibrin
mesh. Taken together, the platelet aggregate and cross-
linked fibrin forms a stable clot, which seals off the site of
injury and prevents excessive blood loss.
Since the blood coagulation system is a potent, highly
effective process, tight regulation of the blood coagulation
system is essential to prevent unnecessary clot formation
[18]. Any perturbations of the regulatory pathways can ac-
cordingly culminate in thrombosis. Coagulation proteases
and molecules can be inhibited by either direct inhibition
of protease activity or through degradation of coagulation
factors. First, circulating protease inhibitors, such as anti-
thrombin, heparin cofactor II, tissue factor pathway
inhibitor (TFPI), and C1 inhibitor, bind with the active site
of proteases and prohibit the protease from cleaving its
target. Table 1 indicates the respective targets for these
inhibitors. Second, coagulation factors can be degraded
through activation of the protein C/protein S pathway,
activation of a disintegrin and metalloproteinase with a
thrombospondin type 1 motif member 13 (ADAMTS13),
or activation of tissue-type plasminogen activator (t-PA).
The protein C/protein S pathway inactivates fVa and
fVIIIa and is catalyzed by the presence of thrombo-
modulin and endothelial protein C receptor (EPCR).Table 1 Targets of coagulation inhibitors
Inhibitor Principal target(s)
Antithrombin Thrombin, fXa, fIXa, fXIa, fXIIa
TFPI fXa, TF/fVIIa
Heparin cofactor II Thrombin
C1 inhibitor fXIa, fXIIa, kallikrein
Protein C pathway Thrombin
Abbreviations: TFPI tissue factor pathway inhibitorADAMTS13 is a matrix metalloproteinase that cleaves
the multimeric strands of von Willebrand factor, dis-
rupting platelet adhesion. t-PA contributes to the final
dissolution of the fibrin-mesh by triggering fibrinolysis
through the conversion of plasminogen to plasmin. Col-
lectively, these individual events come together to ensure
that the blood coagulation system is highly regulated. As a
result of its location, the endothelium plays an essential
role in the development of a clot. Figure 1 illustrates the
contribution of the endothelium to blood coagulation.
The following sections provide an in-depth review of
some of the key components of the blood coagulation sys-
tem that originate from the endothelium.
Endothelial contribution to the blood coagulation
cascade
Traditionally, the blood coagulation system is described
as a “cascade” or “waterfall” of Ca2+-dependent activation
steps that begin with activation of the intrinsic pathway or
extrinsic pathway and culminate in the production of the
penultimate enzyme, thrombin (Fig. 2) [19, 20]. While the
blood coagulation cascade model admittedly provides an
over-simplified view of blood coagulation, it does highlight
all of the essential protein components and is a useful tool
for quickly understanding this otherwise rather intricate
system. Intact endothelial cells express potent inhibitors,
discussed in later sections, to prevent the synthesis and
activity of thrombin. Once endothelial cells become acti-
vated, they play an essential role to the generation of
thrombin through expression of pro-coagulant factors that
contribute to both initiation and propagation of thrombin
generation.
In the blood coagulation cascade, thrombin generation
is initiated by activation of the extrinsic pathway, triggered
by activation of fVII to form fVIIa, or by activation of the
intrinsic pathway, triggered by activation of fXII to form
fXIIa. In the extrinsic pathway, activated endothelial cells
express TF on the cell surface. TF is constitutively
expressed in extravascular tissues, such as fibroblasts and
smooth muscle cells [21] and the phenomenon has been
described as a hemostatic envelope that limits bleeding
after vascular injury [22]. Although TF is not typically
expressed in the intravascular space, activated endothelial
cells and adhered leukocytes may express active TF in
response to vascular injury or inflammatory stimuli. For
example, activated endothelial cells express TF, which has
an important role in the pathogenesis of thrombosis
[23, 24]. TF is also abundantly expressed in atheroscler-
otic plaques and is found in both cellular (macrophages,
vascular smooth muscle cells, and endothelial cells) and
acellular (foam cell-derived debris within the necrotic
core) regions [25, 26]. Furthermore, under experimental
conditions, cultured endothelial cells express TF in
the presence of pro-inflammatory molecules, such as
Fig. 1 Illustration of endothelial control over blood coagulation
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interleukin-1β (IL-1β), thromboxane A2, vascular
endothelial growth factor, and thrombin [27–40]. In
contrast, only a few studies have reported endothelial
TF expression in animal models. While some investi-
gators have reported the presence of TF protein on
the endothelial cells of lipopolysaccharide-treated
mice and rabbits [41, 42], others have been unable to
reproduce the results in similar models [43, 44].
These conflicting observations may in part have
arisen from the different detection methods applied.
Alternatively, TF may exist as an inactive (encrypted)
form that becomes activated (decrypted) upon vascu-
lar injury [45] and this may account for the presence
of TF protein with little to no procoagulant activity.
How and why TF encryption occurs has been a mat-
ter of great debate [45], and is beyond the scope of
this review. Several lines of evidence have suggested
that the effects of endothelial cell-derived TF may not
be confined to the coagulation network. The TF/fVIIacomplex activates protease activated receptor (PAR)-2
[24], which induces a pro-inflammatory response. TF
deficiency has been associated with decreased IL-6
expression via fXa-dependent activation of PAR-2 in a
murine model of sickle cell disease [46]. Furthermore,
microvascular endothelial cells have been observed to
induce angiogenesis and collateral vessel formation
through the release of TF-rich microparticles [47].
The collective data suggest that TF has a multitude
of hematologic and vascular effects although further
work is required to elucidate the origin and role of
endothelial cell-derived TF.
While activated endothelial cells are typically associated
with the extrinsic pathway, they may serve additional roles
with the intrinsic pathway. For example, cultured endo-
thelial cells induce thrombin generation in platelet-poor
plasma. The presence of a TF inhibitor has a limited effect
on thrombin generation whereas low levels of thrombin
are formed in fXII-deficient plasma. Similarly, thrombin
generation is enhanced in patients undergoing coronary
Fig. 2 Succinct schematic overview of the blood coagulation cascade.
f factor, HK high-molecular-weight kininogen, TF tissue factor
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way may be important under specific conditions. The
underlying mechanisms of how endothelial cells affect the
intrinsic pathway is currently unclear although it is plaus-
ible that endothelial cells may in part act as a barrier for
intrinsic factors from inhibition since fXIIa is protected
from inhibition by C1 inhibitor in the presence of endo-
thelial cells [48]. Thus, endothelial cells may be critical
components of both the intrinsic and extrinsic pathways.
Once the blood coagulation cascade is triggered,
thrombin is generated and amplifies its own production
through activation of cofactors fV and fVIII. While fV, as
well as most other pro-coagulant proteins, is derived
from hepatocytes, the origins of fVIII have been elusive.
An early study by Webster et al. demonstrated that ca-
nines with fVIII deficiency (Hemophilia B), that received
liver transplants from normal canines, exhibited reduced
bleeding tendencies compared with non-transplanted
canines [49]. Despite reduced bleeding tendencies, fVIII
deficient canines possessed 50 % of the fVIII plasma
levels compared with normal canines. Similarly, normal
dogs who received liver transplants from hemophilic
dogs also maintained a fVIII level of 50 %. Follow-up in-
vestigations in in vitro settings have provided evidence
suggesting that liver sinusoidal endothelial cells, and nothepatocytes, produce fVIII in culture [50]. Extra-hepatic
endothelial cells may also synthesize fVIII. Norman et al.
and Veltkamp et al. demonstrated that fVIII deficient
animals who received spleen or lung transplantations
had partially restored levels of fVIII in plasma [51, 52],
suggesting that extra-hepatic sources of fVIII existed.
Fahs et al. demonstrated that mice with hepatocyte-
specific deletion of fVIII were indistinguishable from
littermate controls. In contrast, mice with endothelial-
specific deletion of fVIII displayed a severe hemophilic
phenotype with no detectable levels of plasma fVIII
activity [53]. Everett et al. also demonstrated that
endothelial-specific deletion of Lman1 in mice had lower
levels of plasma fVIII compared with their control group
[54]. Conversely, hepatocyte-specific deletion of Lman1
in mice did not reveal any effect on plasma fVIII levels,
supporting the observation that fVIII is synthesized in
multiple types of endothelial cells. Together, these re-
sults provide solid evidence that endothelial cells are the
primary source of fVIII.
Endothelial contribution to platelet adhesion and
aggregation
Platelets play a fundamental role to prevent blood loss
by forming the platelet hemostatic plug, and to serve as
a platform for coagulation factors. Platelet-endothelium
interactions play an integral role in the activation and
regulation of platelets. While an intact endothelium
inhibits the adhesion of platelets, through the release of
nitric oxide and prostaglandin I2, activated endothelial
cells express a variety of molecules and receptors that
increase platelet adhesion to the site of injury. In endo-
thelial cells, Weibel-Palade bodies store VWF, P-selectin,
angiopoietin-2, t-PA, and endothelin-1, which are active
participants of platelet adhesion, leukocyte recruitment,
inflammation modulation, fibrinolysis, and vasocon-
strictor, respectively. Following vascular insult or in the
presence of vasoactive agents such as histamine, brady-
kinin, and thrombin, endothelial Weibel-Palade bodies
fuse with the plasma membrane and release these prod-
ucts into the abluminal space wherein they perform their
respective functions.
VWF, a predominant product of the endothelium, is a
multimeric adhesion glycoprotein. It is synthesized
within the endoplasmic reticulum and processed by the
Golgi complex of endothelial cells, megakaryocytes, and
the α-granules of platelets [55]. In hemostasis, VWF
plays a dual role. First, VWF is essential for platelet
adhesion to collagen at sites of vascular injury. Following
vascular insult, VWF forms long strings of up to several
millimeters in length on the surface of endothelial cells
resulting in ultra-large VWF multimers that readily form
high-strength bonds with platelets via the platelet recep-
tor glycoprotein Ib-V-IX, and stretch along the surface
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ond function of VWF is to stabilize circulating plasma
fVIII [56]. VWF stabilizes fVIII through a non-covalent
interaction, which results in a tightly bound complex
[57]. The importance of VWF in fVIII stabilization is
demonstrated by the rapid clearance of fVIII from the
circulation, resulting in a moderate hemophilia-like
phenotype [58, 59]. Because of its dual role, VWF is an
important contribution to hemostasis by endothelial cells.
VWF secretion has been described as constitutive,
constitutive-like, and regulated, whereby an agonist
acts as the trigger [60–62]. Constitutive secretion
occurs when pro-VWF is released from resting endo-
thelial cells via a canonical constitutive secretory
pathway. Constitutive-like, or basal, secretion of VWF
occurs when VWF is released from storage granules
without stimulation. Despite extensive research, the
exact mechanism by which VWF is secreted remains
poorly defined. Several studies have suggested that
VWF secretion may be dependent on different molecular
pathways. In mice with endothelial cell specific knockout
of G protein subunits (Gα12 and Gα11), thrombin-
induced secretion of VWF was reduced whereas basal
secretion of VWF was decreased in Gα12 knockout mice
[63], suggesting that VWF secretion is G protein
dependent. Another study implicated autophagy, an intra-
cellular process, as a regulator of VWF secretion [64]. In
mice with endothelial cell specific knockout of ATG7, a
critical component of autophagy, VWF secretion is
decreased and maturation of VWF is hindered. In
addition, these mice have prolonged bleeding times com-
pared with control. Interestingly, secretion of VWF is also
influenced by circulating sodium levels [65]. In mice
subjected to water restriction, protein levels of VWF in
the endothelium rose along with an increased number of
microthrombi inside capillaries [65].
Endothelial regulation of the blood coagulation system
Under physiological conditions, the endothelium prevents
thrombosis by providing a surface that discourages the
attachment of cells and clotting proteins [66]. The endo-
thelium regulates clot formation in part via its activation
of the intravascular PARs. PARs exist as four isoforms,
PAR-1, PAR-2, PAR-3, and PAR-4, and are expressed in
arterial and venous endothelial cells [67–69]. Acute
release of endothelial products in coagulation is largely
mediated via PAR-1 [70]. Endothelial PARs serve as
sensors for proteases and initiate a cascade of cell signals
upon activation by thrombin, APC, fXa, the TF/fVIIa/fXa
complex, high concentrations of plasmin, and matrix
metalloproteases [69–71]. First, thrombin-mediated acti-
vation of PAR-1 is responsible for the production of nitric
oxide and prostacyclin, which limits platelet activation.
Second, thrombin-mediated activation of PAR-1 inducesthe activation of Weibel-Palade bodies, releasing VWF
and t-PA. Lastly, thrombin-mediated activation of PAR-1
mediates the surface exposure of TF. Taken together,
PAR-1 plays an important role in the pro-coagulant
response upon stimulation.
An intact and healthy endothelium expresses various
anticoagulants, such as TFPI, thrombomodulin, EPCR,
and heparin-like proteoglycans [72]. Endothelial cells
also secrete ectonucleotidase CD39/NTPDase1, which
metabolizes the platelet agonist ADP, and platelet inhibi-
tors, such as nitric oxide and prostacyclin [66]. As such,
the endothelium actively regulates the powerful coagula-
tion response through equally potent inhibitory processes.
One of the most important endothelium-derived
inhibitors of the blood coagulation cascade is TFPI. A
detailed overview of the structure and function of TFPI
is extensively reviewed elsewhere [73]. Briefly, TFPI is a
Kunitz-type protease inhibitor that inhibits the coagula-
tion cascade by direct inhibition of free fXa and the TF/
fVIIa/fXa complex. TFPI is present in endothelial cells
but can also be found in megakaryocytes and platelets
[73], and can be released upon treatment with heparin
[74–76]. While TFPI exists as three isoforms (α, β and δ),
TFPIα and TFPIβ are the predominant isoforms. TFPI
also possesses a cofactor, Protein S. Protein S aids in the
TFPI-induced inhibition of fXa and stabilizes the TFPI/
fXa inhibitory complex thereby delaying thrombin gener-
ation by prothrombinase [77]. However, the catalytic ac-
tivity of protein S is limited to platelet- and endothelial
cell-derived TFPIα whereas protein S has no effect on cell
surface-associated TFPI [77]. The importance of TFPI in
hemostasis has been made very apparent in in vitro and
animal models. Early studies demonstrated that inhibition
of TFPI decreases the time to clot in normal plasma, sug-
gesting that TFPI is an important regulator of coagulation.
Mice with systemic homozygous deletion of the first
Kunitz domain of TFPI (TFPItm1Gjb; tfpi−/−) suffer from
intrauterine lethality due to coagulopathy [78]. Those with
hematopoietic-specific deletion of TFPI experience
increased clot volume following vascular injury, whereas
mice with endothelial-specific deletion of TFPI have
decreased time to vascular occlusion following ferric
chloride-induced injury [79]. Complete TFPI deficiency is
a condition that has not been reported in humans, likely
due to embryonic lethality. Patients with TFPI levels at or
less than the 10th percentile of the normal reference range
for TFPI are at slightly increased risk for venous
thrombosis and coronary heart disease [80, 81]. This
corroborates the notion that endothelium-derived
TFPI is important for prevention of thrombosis.
Once the cascade is initiated, thrombin generation is
amplified in the presence of activated cofactors. Since
fVa and fVIIIa are essential cofactors for the amplifica-
tion of thrombin production, their inactivation provides
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This can be achieved through thrombin-mediated activa-
tion of the protein C pathway, which is catalyzed by
endothelial cells via thrombomodulin and EPCR.
Thrombomodulin is a 60-kDa transmembrane protein
that is predominately synthesized by endothelial cells
and expressed in all tissues, except for the microvascula-
ture of the brain. Its transcription is regulated by shear
stress and involves the transcription factor KLF-2 [82].
Thrombomodulin has been implicated in coagulation,
inflammation, cancer development, and embryogenesis.
Evidence to date suggests that thrombomodulin possesses
three independent anticoagulant activities: catalyzing
thrombin-induced activation of protein C to activated
protein C, binding with thrombin to prevent conversion
of fibrinogen to fibrin and activation of platelets, fV, fVIII,
fXI, and fXIII, and catalyzing the inhibition of thrombin
by antithrombin [83]. As the concentration of thrombin
rises during coagulation, thrombomodulin forms a
complex with thrombin to create the thrombin-
thrombomodulin complex that proteolytically activates
protein C and generates activated protein C, which
confers anticoagulant activities [84]. Activated protein C
degrades fVa and fVIIIa, and thus, attenuates thrombin
generation. The thrombin-thrombomodulin complex
enhances the conversion of protein C to activated protein
C by 1000-fold compared with thrombin alone [85].
Although thrombin-thrombomodulin-mediated protein C
activation is relatively efficient in the microvasculature,
protein C cleavage in larger vessels requires the presence
of EPCR, which is primarily localized on the endothelial
layer of larger vessels [16]. EPCR is a type 1 transmem-
brane glycoprotein that possesses a similar homology to
the major histocompatibility complex-class 1/CD1 family
of molecules [86]. EPCR recruits protein C at the endo-
thelial cell surface thereby facilitating the interaction
between protein C and the thrombin-thrombomodulin
complex. In the presence of EPCR, the conversion of pro-
tein C to activated protein C is increased by 20-fold com-
pared with the thrombin-thrombomodulin complex alone
[87]. EPCR has also been shown to bind with activated
protein C [88]. The importance of EPCR is highlighted in
studies involving mice. Mice with total deficiency in EPCR
die in utero [89], suggesting that EPCR is not only
important for suppression of thrombosis but is essential
for normal embryonic development. Taken together,
thrombin-mediated activation of protein C requires the
presence of thrombomodulin and EPCR to efficiently
generate activated protein C.
Endothelial contribution to clot resolution
Once the wound is repaired, endothelial cells release
pro-fibrinolytic molecules to degrade the clot and metal-
loproteases to cleave platelet aggregates. Dissolution ofthe clot is induced by fibrinolytic agents, such as t-PA
and urokinase-type PA (u-PA). Although t-PA and u-PA
perform the same function, t-PA is predominantly found
in endothelial cells while u-PA is expressed in endothe-
lial cells, macrophages, renal epithelial cells and some
tumor cells. For simplicity, we primarily focus on t-PA
since endothelial cells are the primary source of t-PA. t-
PA is a 70-kDa protein that catalyzes the degradation of
fibrin within the clot [90]. t-PA performs this function
by activating the fibrinolytic system through conversion
of plasminogen to plasmin in blood and body cavities
[91]. In cultured endothelial cells, there is evidence that
t-PA is stored in two types of storage granules: Weibel-
Palade bodies [92] and small storage granules [93]. After
wound repair is complete, the high local increase in t-PA
at the site of thrombin generation allows for efficient re-
moval of fibrin deposits at the luminal side of an intact
vascular endothelium and is important for reducing tis-
sue damage. The importance of t-PA has been demon-
strated in t-PA deficient mice wherein clot lysis was
impaired, especially when combined with u-PA defi-
ciency [94, 95]. In experimental primate models of acute
disseminated intravascular coagulation, plasma concentra-
tions of t-PA was acutely increased by more than two or-
ders of magnitude, due to thrombin-mediated release
from storage granules in endothelial cells [96]. Thus, t-PA
provides an essential method for removal of blood clots.
In a similar fashion, dissolution of platelet aggregates
is mediated by ADAMTS13 [97]. Endothelial cells
produce and release functionally active ADAMTS13, a
zinc/calcium VWF-specific metalloprotease, and are
an important source of plasma ADAMTS13 [98]. The
importance of ADAMTS13 is highlighted by the observa-
tion that patients with thrombotic thrombocytopenia
purpura, the levels of ADAMTS13 is severely reduced or
absent [99]. This lack of ADAMTS13 may be due to inad-
equate production/release of ADAMTS13 or the activity
ADAMTS13 is inhibited by auto-antibodies.
Endothelial contribution to tissue repair and angiogenesis
While the blood coagulation system forms the stable clot
that stems the loss of blood, it also contributes toward
subsequent healing processes such as tissue repair and
angiogenesis. Since endothelial cells are important com-
ponent of blood vessels, they can be triggered to induce
angiogenesis upon stimulation. For example, in addition
to its anti-coagulant abilities, activated protein C has
been shown to stimulate angiogenesis in brain endothe-
lium [100]. Second, cross-linked fibrin serves as a scaffold
for endothelial cells to synthesize new blood vessels
[101, 102]. Third, platelets contain a rich source of
vasoactive agents and chemokines, such as serotonin,
thromboxane A2, platelet activating factor and RANTES,
and pro-angiogenic growth factors, such as VEGF, all of
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These compounds stimulate endothelial cell proliferation
and promote the growth of new blood vessels. Lastly, the
expression of TF has been shown to induce tumor angio-
genesis in colorectal cancer and breast cancer models
through TF-fVIIa-dependent PAR-2 activation [105–107],
which induces the expression of VEGF, IL-8, MMP-7, and
CXCL-1. In the past 10 years, studies have highlighted the
role of a TF isoform, alternatively spliced TF [108–110],
which displays no pro-coagulant activity but may play a
prominant role in promoting angiogenesis. Taken
together, the role of the coagulation system plays a major
role in the development of angiogenesis.
Endothelial contribution to aberrant clot formation
The endothelium is an essential component of the blood
coagulation system and necessary to maintain hemostasis.
However, endothelial dysfunction can occur in response
to a variety of conditions, including elevated cholesterol,
diabetes or smoking, which can induce vascular in-
flammation. Endothelial dysfunction is responsible for
inflammation and blood coagulation, and is associated
with cardiovascular disease, such as hypertension, cor-
onary artery disease, chronic heart failure, peripheral
artery disease, diabetes, chronic kidney failure, and
viral infections. During endothelial dysfunction, endothe-
lial cells become activated and contribute to the pathogen-
esis of thrombosis. For example, hypoxic conditions often
lead to endothelial dysfunction. As such, hypoxia has
been shown to promote the release of VWF from
Weibel-Palade bodies in endothelial cells. Inflammation
has also been associated with endothelial dysfunction and
can be accompanied by thrombosis. For example, in vitro
and in vivo studies have demonstrated that pro-
inflammatory cytokines, such as TNF-α and IL-1, up-
regulate the production of TF and VWF, while attenuating
the expression of thrombomodulin and nitric oxide andTable 2 Endothelial products in coagulation
Protein/Receptor Function
PAR Induces release of nitric oxide an
TF Triggers the production of throm
fVIII/fVIIIa Amplifies the production of throm
VWF Tethers platelets to collagen via g
Stabilizes fVIII in plasma
TFPI Inhibits the activity of the TF/fVIIa
Thrombomodulin Eliminates the activity of thrombi
Induces the activation of the pro
EPCR Catalyzes conversion of Protein C
t-PA Triggers fibrinolysis by converting
Abbreviations: EPCR endothelial protein C receptor, f factor, PAR protease-activated r
plasminogen activator, VWF von Willebrand factorprostaglandin I2. In rabbits, immunodepletion of TFPI
leads to increased susceptibility to disseminated intravas-
cular coagulation (DIC) [111], and generalized Schwartz-
man reaction, characterized by fibrin deposition and
hemorrhagic necrosis in kidneys following infusion of TF
[112]. The Protein C pathway has also been implicated in
the development of disseminated intravascular coagula-
tion with associated organ dysfunction. Patients with sys-
temic inflammation show an impaired protein C system
due to impaired protein C synthesis and impaired protein
C activation. While protein C is synthesized by hepato-
cytes, endothelial cells can regulate protein C activation
through the expression of thrombomodulin. As such,
thrombomodulin levels are significantly down-regulated
by the presence of pro-inflammatory cytokines, such as
TNF-α and IL-1, resulting in diminished protein C activa-
tion. These events result in a shift from anti-thrombotic
to pro-thrombotic conditions.Conclusions
The endothelium is a dynamic lining that regulates the
complex interplay of the coagulation system with the
surrounding cells and tissues. When stressed beyond a
certain threshold, the quiescent endothelium initiates
numerous mechanisms to induce clotting (e.g. by
expression of TF and fVIII) and anticoagulation (e.g. by
expression of thrombomodulin, EPCR, and PAR-type
receptors) (Table 2). Concomitantly, activated endothe-
lial cells recruits platelets to the site of injury (e.g. by ex-
pression of VWF), where it serves as a support surface
for formation of pro-coagulant complexes and platelet
aggregation. The biochemical processes described above
highlight the critical contributions of multiple endothe-
lial molecules in hemostasis and thrombosis, thereby
underscoring the central role of the endothelium in
these processes.d prostacyclin I2, activation of Weibel-Palade bodies, and expression of TF
bin through activation of fX when in complex with fVIIa
bin when in complex with fIXa
lycoprotein VI on platelets
complex and fXa
n when in complex
tein C pathway
to activated Protein C
plasminogen to plasmin
eceptor, TF tissue factor, TFPI tissue factor pathway inhibitor, t-PA tissue-type
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APC: Activated protein C; EPCR: Endothelial protein C receptor; f: Factor;
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